Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Enterprise Value (2020 - 2025)

Oncology Institute's Enterprise Value history spans 6 years, with the latest figure at -$33.6 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 32.42% year-over-year to -$33.6 million; the TTM value through Dec 2025 reached -$33.6 million, up 32.42%, while the annual FY2025 figure was -$33.6 million, 32.42% up from the prior year.
  • Enterprise Value reached -$33.6 million in Q4 2025 per TOI's latest filing, down from -$27.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$11.5 million in Q3 2021 to a low of -$115.2 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$54.9 million, with a median of -$48.5 million recorded in 2024.
  • Peak YoY movement for Enterprise Value: plummeted 1820.21% in 2021, then surged 45.77% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$115.2 million in 2021, then soared by 35.92% to -$73.8 million in 2022, then dropped by 12.26% to -$82.9 million in 2023, then surged by 40.05% to -$49.7 million in 2024, then soared by 32.42% to -$33.6 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Enterprise Value are -$33.6 million (Q4 2025), -$27.7 million (Q3 2025), and -$30.3 million (Q2 2025).